Paternal exposure to most IBD medications not linked to adverse neonatal outcomes

SAN DIEGO — Paternal exposure to the majority of therapies for inflammatory bowel disease did not increase the risk for adverse neonatal outcomes, according to data from a small patient subset presented at Digestive Disease Week 2022.
“Over the past couple of decades, our ability to care for pregnant women with IBD has improved considerably; we have a good understanding of risk factors and we have learned a lot about the safety of medications that we use for our pregnant mothers,” Grant E. Barber, MD, resident physician at Stanford University Hospital, told attendees. “An

SAN DIEGO — Paternal exposure to the majority of therapies for inflammatory bowel disease did not increase the risk for adverse neonatal outcomes, according to data from a small patient subset presented at Digestive Disease Week 2022.
“Over the past couple of decades, our ability to care for pregnant women with IBD has improved considerably; we have a good understanding of risk factors and we have learned a lot about the safety of medications that we use for our pregnant mothers,” Grant E. Barber, MD, resident physician at Stanford University Hospital, told attendees. “An